U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C21H29N3O
Molecular Weight 339.4745
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DISOPYRAMIDE

SMILES

CC(C)N(CCC(C(N)=O)(C1=CC=CC=C1)C2=CC=CC=N2)C(C)C

InChI

InChIKey=UVTNFZQICZKOEM-UHFFFAOYSA-N
InChI=1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)

HIDE SMILES / InChI

Molecular Formula C21H29N3O
Molecular Weight 339.4745
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/disopyramide.html

Disopyramide is an antiarrhythmic drug indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia that are life-threatening. In man, Disopyramide at therapeutic plasma levels shortens the sinus node recovery time, lengthens the effective refractory period of the atrium, and has a minimal effect on the effective refractory period of the AV node. Little effect has been shown on AV-nodal and His-Purkinje conduction times or QRS duration. However, prolongation of conduction in accessory pathways occurs. Disopyramide is a Type 1A antiarrhythmic drug (ie, similar to procainamide and quinidine). It inhibits the fast sodium channels. In animal studies Disopyramide decreases the rate of diastolic depolarization (phase 4) in cells with augmented automaticity, decreases the upstroke velocity (phase 0) and increases the action potential duration of normal cardiac cells, decreases the disparity in refractoriness between infarcted and adjacent normally perfused myocardium, and has no effect on alpha- or beta-adrenergic receptors. It is used for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, ventricular pre-excitation and cardiac dysrhythmias. It is a Class Ia antiarrhythmic drug.

Originator

Curator's Comment: Introduced as Rythmodan by Cassenne, France, in 1969

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
52.5 µM [IC50]
Target ID: KATP channels, Mus musculus
4.8 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DISOPYRAMIDE PHOSPHATE

Approved Use

indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening.

Launch Date

4.7779201E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
3.08 mg/L
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DISOPYRAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
27.1 μg × h/mL
2 mg/kg 1 times / day multiple, oral
dose: 2 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DISOPYRAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.8 h
2 mg/kg 1 times / day multiple, oral
dose: 2 mg/kg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
DISOPYRAMIDE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
8 h
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DISOPYRAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
35%
200 mg single, oral
dose: 200 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DISOPYRAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
432 mg 1 times / day steady, oral (median)
Dose: 432 mg, 1 times / day
Route: oral
Route: steady
Dose: 432 mg, 1 times / day
Sources:
unhealthy, 47 + 20 years
n = 118
Health Status: unhealthy
Condition: obstructive hypertrophic cardiomyopathy
Age Group: 47 + 20 years
Sex: M+F
Population Size: 118
Sources:
Disc. AE: Dry mouth, Prostatism...
AEs leading to
discontinuation/dose reduction:
Dry mouth (7%)
Prostatism (7%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Dry mouth 7%
Disc. AE
432 mg 1 times / day steady, oral (median)
Dose: 432 mg, 1 times / day
Route: oral
Route: steady
Dose: 432 mg, 1 times / day
Sources:
unhealthy, 47 + 20 years
n = 118
Health Status: unhealthy
Condition: obstructive hypertrophic cardiomyopathy
Age Group: 47 + 20 years
Sex: M+F
Population Size: 118
Sources:
Prostatism 7%
Disc. AE
432 mg 1 times / day steady, oral (median)
Dose: 432 mg, 1 times / day
Route: oral
Route: steady
Dose: 432 mg, 1 times / day
Sources:
unhealthy, 47 + 20 years
n = 118
Health Status: unhealthy
Condition: obstructive hypertrophic cardiomyopathy
Age Group: 47 + 20 years
Sex: M+F
Population Size: 118
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Drug as perpetrator​

Drug as perpetrator​

Drug as victimTox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
[Torsades de pointes ventricular tachycardia induced by disopyramide at therapeutic serum concentration].
1992 Aug 20
Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone.
1992 Nov
Population pharmacokinetics, protein binding and antiarrhythmic effects of disopyramide enantiomers in arrhythmic patients.
2001
[Acute intoxication with disopyramide: case report with literature review].
2001 Nov-Dec
Disopyramide: interactions with marcolide antibiotics.
2001 Oct
Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs.
2002
Strategy for the management of vasovagal syncope.
2002
Risk of mortality in a cohort of patients newly diagnosed with chronic atrial fibrillation.
2002
Cisapride reverses the anticholinergic effect of disopyramide on the isolated guinea-pig urinary bladder.
2002 Apr
[Role amiodarone in sinus rhythm maintenance after successful cardioversion in patients with chronic non-valvular atrial fibrillation].
2002 Dec
MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs.
2002 Dec
Age- and gender-related differences in carbohydrate concentrations of alpha1-acid glycoprotein variants and the effects of glycoforms on their drug-binding capacities.
2002 Dec
Disopyramide-induced neuropathy.
2002 Feb 26
Effective disopyramide treatment in a boy with mid-ventricular hypertrophic obstructive cardiomyopathy.
2002 Jul
Quantification of pilsicainide in serum by capillary electrophoresis.
2002 Jul 20
[Antiarrhythmic drugs in atrial fibrillation].
2002 Jun 15
What is the minimal pacing rate that prevents torsades de pointes? Insights from patients with permanent pacemakers.
2002 Nov
[Molecular diversity of organic cation transporter (OCT) mediating renal excretion of drugs].
2002 Nov
Atrial fibrillation threshold predicted long-term efficacy of pharmacological treatment of patients without structural heart disease.
2002 Oct
Development and use of a computer program to detect potentially inappropriate prescribing in older adults residing in Canadian long-term care facilities.
2002 Oct 14
Effects of disopyramide and mexiletine on the terminal repolarization process of the in situ heart assessed using the halothane-anesthetized in vivo canine model.
2002 Sep
Maintaining stability of sinus rhythm in atrial fibrillation: antiarrhythmic drugs versus ablation.
2002 Sep
[Anti-arrhythmic therapy: diagnostic possibilities of signal-averaged electrocardiography and heart rate variability].
2003
[Comparison of the efficacies of disopyramide, cibenzoline and aprindine for the termination of paroxysmal and persistent atrial fibrillation in elderly and non-elderly patients].
2003 Apr
Effects of orthostatic self-training on head-up tilt testing for the prevention of tilt-induced neurocardiogenic syncope: comparison of pharmacological therapy.
2003 Apr
Capillary electrophoretic study on pH dependence of enantioselective disopyramide binding to genetic variants of human alpha1-acid glycoprotein.
2003 Aug
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
2003 Aug 18
Abnormal response to sodium channel blockers in patients with Brugada syndrome: augmented localised wall motion abnormalities in the right ventricular outflow tract region detected by electron beam computed tomography.
2003 Feb
The effect of commonly used drugs on angiogenesis.
2003 Jan-Feb
Inhibitory effect of erythromycin on potassium currents in rat ventricular myocytes in comparison with disopyramide.
2003 Jul
Interaction of quinidine, disopyramide and metoprolol with melanin in vitro in relation to drug-induced ocular toxicity.
2003 Jul
Multivariate analysis of risk factors for QT prolongation following subarachnoid hemorrhage.
2003 Jun
[Drug therapy of atrial fibrillation].
2003 Jun 15
Safety and feasibility of a clinical pathway for the outpatient initiation of antiarrhythmic medications in patients with atrial fibrillation or atrial flutter.
2003 Jun 15
Characterisation of recombinant HERG K+ channel blockade by the Class Ia antiarrhythmic drug procainamide.
2003 Jun 27
Comparison of the effect of class IA antiarrhythmic drugs on transmembrane potassium currents in rabbit ventricular myocytes.
2003 Mar
[Relationship between duration of arrhythmia and subsequent preventive effect of disopyramide after cardioversion in patients with symptomatic paroxysmal and persistent atrial fibrillation].
2003 Sep
Randomized clinical trials of neurally mediated syncope.
2003 Sep
Atrial fibrillation: rate control often better than rhythm control.
2004 Apr
Recurrent syncopic episodes as a consequence of combined Brugada syndrome and paroxysmal atrial fibrillation. Which is the therapy of choice?
2004 Apr
Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study.
2004 Aug
Simultaneous supraventricular tachycardias in both fetuses of a twin gestation.
2004 Dec
Two cases of ventricular tachycardia with congenital left ventricular malformation in an adult.
2004 Feb
Repolarization abnormality in idiopathic ventricular fibrillation: assessment using 24-hour QT-RR and QaT-RR relationships.
2004 Jan
Effects of class I antiarrhythmic drugs on the digitalis-induced triggered activity arrhythmia model: a rationale for the short-term use of class I drugs against triggered arrhythmias.
2004 Jan
Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels.
2004 Jul
Effects of antiarrhythmic agents on left ventricular function during exercise in patients with chronic left ventricular dysfunction.
2004 May
Pharmacological treatment of reflex syncope.
2004 Oct
Appropriate dosing of antiarrhythmic drugs in Japan requires therapeutic drug monitoring.
2005 Feb
A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system.
2005 Feb
Patents

Sample Use Guides

Usual Adult Dose for Arrhythmias 400-800 mg/day. The recommended dose for most adults is 600 mg/day. Patients < 50 kg may be given 400 mg/day.
Route of Administration: Oral
Disopyramide (10-100 uM) led to increases in the action potential duration (APD) at 90% repolarization level in rat ventricular myocytes.
Substance Class Chemical
Created
by admin
on Thu Jul 06 00:59:38 UTC 2023
Edited
by admin
on Thu Jul 06 00:59:38 UTC 2023
Record UNII
GFO928U8MQ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DISOPYRAMIDE
EP   INN   MART.   MI   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
DISOPYRAMIDE [USAN]
Common Name English
(±)-DISOPYRAMIDE
Common Name English
LISPINE
Brand Name English
2-PYRIDINEACETAMIDE, .ALPHA.-(2-(BIS(1-METHYLETHYL)AMINO)ETHYL)-.ALPHA.-PHENYL-
Systematic Name English
DISOPYRAMIDE [VANDF]
Common Name English
DISOPYRAMIDE [MART.]
Common Name English
RYTHMODAN P
Brand Name English
α-[2-(Diisopropylamino)ethyl]-α-phenyl-2-pyridineacetamide
Systematic Name English
4-DIISOPROPYLAMINO-2-PHENYL-2-(2-PYRIDYL)BUTYRAMIDE
Systematic Name English
DICORANTIL
Brand Name English
RITMILEN
Brand Name English
SEARLE-703
Common Name English
DISOPYRAMIDE [JAN]
Common Name English
SC-7031
Code English
Disopyramide [WHO-DD]
Common Name English
DISOPYRAMIDE [EP MONOGRAPH]
Common Name English
ISORYTHM
Brand Name English
DL-DISOPYRAMIDE
Common Name English
DISOPYRAMIDE [MI]
Common Name English
disopyramide [INN]
Common Name English
(RS)-DISOPYRAMIDE
Common Name English
H-3292
Code English
Classification Tree Code System Code
WHO-ATC C01BA03
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
NCI_THESAURUS C47793
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
NDF-RT N0000175426
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
LIVERTOX NBK548693
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
WHO-VATC QC01BA03
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
NCI_THESAURUS C93038
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
Code System Code Type Description
CAS
3737-09-5
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
PRIMARY
DRUG BANK
DB00280
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
PRIMARY
MESH
D004206
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
PRIMARY
PUBCHEM
3114
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
PRIMARY
EPA CompTox
DTXSID1045536
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
PRIMARY
NCI_THESAURUS
C61730
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
PRIMARY
WIKIPEDIA
DISOPYRAMIDE
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
PRIMARY
DAILYMED
GFO928U8MQ
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
PRIMARY
RXCUI
3541
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
PRIMARY RxNorm
CHEBI
4657
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
PRIMARY
DRUG CENTRAL
926
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
PRIMARY
EVMPD
SUB07237MIG
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
PRIMARY
ChEMBL
CHEMBL517
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
PRIMARY
CAS
74427-45-5
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
SUPERSEDED
INN
1307
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
PRIMARY
ECHA (EC/EINECS)
223-110-2
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
PRIMARY
SMS_ID
100000082359
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
PRIMARY
LACTMED
Disopyramide
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
PRIMARY
MERCK INDEX
M4672
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
PRIMARY Merck Index
IUPHAR
7167
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
PRIMARY
FDA UNII
GFO928U8MQ
Created by admin on Thu Jul 06 00:59:38 UTC 2023 , Edited by admin on Thu Jul 06 00:59:38 UTC 2023
PRIMARY
Related Record Type Details
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
ENANTIOMER -> RACEMATE
TRANSPORTER -> INHIBITOR
BINDER->LIGAND
TRANSPORTER -> INHIBITOR
ENANTIOMER -> RACEMATE
SALT/SOLVATE -> PARENT
TRANSPORTER -> INHIBITOR
Related Record Type Details
METABOLITE -> PARENT
MAJOR
PLASMA; URINE
METABOLITE -> PARENT
Related Record Type Details
ACTIVE MOIETY